An growing variety of medication of European origin have been in-licensed to Chinese language biotechnology corporations.
During the last 5 years, a gradual improve within the variety of yearly in-licensed property from Europe will be noticed. Whereas solely 30 medication had been in-licensed in 2016, the quantity greater than quadrupled in 2021 (YTD) to 121.
Most sought-after property have been in orphan ailments, oncology and CNS.